Health Trials

Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)

1

Review clinical trials related to Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab (SOT-R) and rituximab plus chemotherapy (SOT-R+C) or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.

Participants needed: 115
Trial details
Phase: Phase 3Biological sex: AllType: InterventionalSponsor: Pierre Fabre MedicamentUpdated: May 22, 2026Locations: 71
Eligibility criteria

Prior SOT of kidney, liver, heart, lung, pancreas, small bowel, or any combinati... [+12]

Currently active Burkitt, T-cell, NK/T-cell lymphoma/LPD, Hodgkin, plasmablastic... [+11]

Read more